Introduction to Fibrinogen Activity Testing

Fibrinogen (Factor I) is a critical glycoprotein synthesized by the liver, playing a fundamental role in the body’s coagulation cascade. When vascular injury occurs, fibrinogen is converted into fibrin by the enzyme thrombin, forming a stable, cross-linked meshwork that acts as the scaffold for blood clots. The Fibrinogen Activity test is a specialized laboratory assessment that measures the functional ability of fibrinogen to form this clot, rather than merely measuring the total concentration of the protein.

As an orthopedic specialist, understanding fibrinogen dynamics is essential, particularly in the perioperative setting. Whether managing trauma patients or preparing for elective joint replacement, clinicians must evaluate the patient’s hemostatic potential to mitigate risks of excessive bleeding or thrombotic complications. This guide provides an exhaustive overview of the clinical utility, physiological significance, and diagnostic interpretation of Fibrinogen Activity.

The Mechanism of Fibrinogen Activity

To understand the test, one must understand the coagulation cascade. Fibrinogen is a large, dimeric protein consisting of three pairs of polypeptide chains ($A\alpha$, $B\beta$, and $\gamma$). The Fibrinogen Activity assay—often referred to as the Clauss method—is the gold standard for clinical diagnostics.

The Clauss Method Principle

The Clauss assay is a kinetic, clotting-based test. In this procedure:
1. A patient’s plasma sample is diluted to minimize the influence of inhibitors (such as heparin).
2. An excess of thrombin is added to the plasma.
3. The time taken for the clot to form is measured.
4. The clotting time is inversely proportional to the concentration of functional fibrinogen.

By comparing the clotting time against a standardized calibration curve, the laboratory determines the "functional" level of fibrinogen. Unlike immunological assays (e.g., ELISA), which measure total protein concentration regardless of whether it is functional, the Clauss method ensures that the protein present is actually capable of forming a stable clot.

Clinical Indications and Diagnostic Usage

Fibrinogen Activity is not a routine screening test for the general population but is highly indicated in specific clinical scenarios involving hemorrhage, thrombosis, or chronic inflammatory states.

Primary Clinical Indications

• Pre-operative Assessment: Essential for patients undergoing high-risk orthopedic surgeries (e.g., spinal fusion, total hip arthroplasty) to baseline clotting potential.
• Disseminated Intravascular Coagulation (DIC): Used as part of a panel to monitor the consumption of clotting factors.
• Hemorrhagic Diathesis: Investigation of unexplained bleeding, particularly in patients with suspected hypofibrinogenemia or dysfibrinogenemia.
• Monitoring Thrombolytic Therapy: Assessing the systemic fibrinolytic state during or after the administration of clot-busting agents.
• Inflammatory Monitoring: Fibrinogen is an acute-phase reactant; levels rise significantly during systemic inflammation, infection, or tissue necrosis.

When to Order the Test

Reference Ranges and Interpretation

Reference ranges can vary slightly depending on the laboratory’s specific methodology and reagents. Generally, the accepted adult reference range is:

Normal Range: 200–400 mg/dL (2.0–4.0 g/L)

Interpreting Abnormal Levels

Decreased Fibrinogen (< 200 mg/dL)

Decreased activity may be secondary to consumption or decreased production.
* Acquired: DIC, liver failure (cirrhosis, hepatitis), severe malnutrition, or massive hemorrhage (dilutional effect).
* Congenital: Afibrinogenemia (complete absence), hypofibrinogenemia (low levels), or dysfibrinogenemia (functional impairment).

Elevated Fibrinogen (> 400 mg/dL)

Fibrinogen acts as an acute-phase reactant. Elevation is often non-specific but indicative of systemic stress.
* Inflammation: Rheumatoid arthritis, acute infections, or post-surgical recovery.
* Malignancy: Certain cancers can stimulate fibrinogen production.
* Metabolic: Pregnancy, smoking, and obesity are frequently associated with higher baseline levels.

Specimen Collection and Interfering Factors

Quality control in the pre-analytical phase is paramount for coagulation studies.

Collection Guidelines

1. Tube Type: Use a light blue-top tube containing 3.2% sodium citrate.
2. Ratio: The blood-to-anticoagulant ratio must be strictly 9:1. Overfilling or underfilling the tube will invalidate the results.
3. Handling: The sample should be processed promptly. If testing is delayed, plasma must be separated via centrifugation and frozen at -20°C or colder.

Interfering Factors

• Heparin: High levels of heparin can artificially prolong clotting times, leading to a falsely low fibrinogen result.
• Fibrin Degradation Products (FDPs): High levels of FDPs (as seen in DIC) can interfere with fibrin polymerization.
• Hemolysis: Hemolyzed samples may activate the coagulation cascade prematurely, skewing results.
• Medications: Estrogen therapy and oral contraceptives are known to increase fibrinogen levels.

Risks, Side Effects, and Contraindications

There are no direct risks to the patient associated with the Fibrinogen Activity test itself, as it is a standard blood draw. However, clinicians must consider the following:

• Contraindications: There are no absolute contraindications to drawing blood for this test, though patients with severe coagulopathy should be monitored for hematoma formation at the venipuncture site.
• Clinical Risk: The primary risk lies in misinterpretation. Low fibrinogen levels in a surgical patient require immediate intervention (cryoprecipitate or fibrinogen concentrate). Failure to recognize critical hypofibrinogenemia can lead to catastrophic perioperative hemorrhage.

Frequently Asked Questions (FAQ)

1. What is the difference between Fibrinogen Antigen and Fibrinogen Activity?

Fibrinogen Antigen measures the total amount of protein present using antibodies, while Fibrinogen Activity (Clauss method) measures the protein's functional ability to clot.

2. Can I eat before a Fibrinogen Activity test?

Generally, no special fasting is required, but you should inform your doctor of all medications, as some (like anticoagulants) can interfere with the results.

3. Does pregnancy affect Fibrinogen levels?

Yes. Fibrinogen is a positive acute-phase reactant and naturally rises during pregnancy, often reaching levels double that of non-pregnant individuals.

4. What is the treatment for low Fibrinogen?

Treatment usually involves the administration of cryoprecipitate, fresh frozen plasma (FFP), or purified fibrinogen concentrates, depending on the severity and underlying cause.

5. Is Fibrinogen a marker for heart disease?

Elevated fibrinogen levels are considered an independent risk factor for cardiovascular disease, as they increase blood viscosity and promote thrombus formation.

6. Why is Fibrinogen considered an "acute-phase reactant"?

It is produced by the liver in response to inflammatory cytokines (such as IL-6). During infection or injury, the body increases production to facilitate rapid wound healing and clotting.

7. What if my Fibrinogen is slightly high?

A slightly elevated level is often a sign of mild inflammation or stress and may not require specific treatment, but it should be correlated with other clinical findings like CRP or ESR.

8. How long does it take to get results?

In most modern hospital laboratories, Fibrinogen Activity results are available within 1 to 4 hours.

9. Can liver disease cause low Fibrinogen?

Yes. Since the liver is the site of fibrinogen synthesis, advanced liver disease (such as cirrhosis) frequently leads to decreased production of clotting factors.

10. Does aspirin affect Fibrinogen Activity?

Aspirin primarily affects platelet function (aggregation) and typically does not interfere with the fibrinogen clotting time assay.

Conclusion

The Fibrinogen Activity test is an indispensable tool in the diagnostic armamentarium of the orthopedic specialist and the general practitioner alike. By providing a functional assessment of the blood’s ability to form a clot, it allows for proactive management of surgical patients and diagnostic clarity in complex hematological cases. When combined with a thorough clinical history and physical examination, this test ensures that clinicians can make informed decisions regarding blood product transfusion and thrombotic risk mitigation. Always ensure proper specimen handling to maintain the integrity of the coagulation profile, and consult with a hematologist when results fall outside the expected clinical range.